NCT06733077 Development of Digital Services for Parkinson's Disease
| NCT ID | NCT06733077 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Exeter |
| Condition | Healthy Controls |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-12-20 |
| Primary Completion | 2026-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2024-12-20 with a primary completion date of 2026-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this project, ocular motor, pupil and gait data in people with Parkinson's disease (PD) will be collected in order to develop machine learning models for the diagnosis and monitoring of PD. With this, the investigators aim to advance the state of the art in PD diagnosis and monitoring. By integrating the principles of machine learning with high-quality sensor data, more accurate and earlier diagnosis could potentially be achieved. Ocular motor and pupil data will be collected with the standard clinical examination and with neos, a medical device approved for objective ocular motor and pupil measurement. Gait will be collected using an IMU sensor and GaitQ senti, a consumer device that allows for an objective and continuous remote gait monitoring.
Eligibility Criteria
Inclusion criteria Participants with Parkinson's \[Phase 1,2,3,4\] * Diagnosis of idiopathic Parkinson's disease (UK Brain Bank Criteria) or other appropriate condition specific scale \[stroke, multiple sclerosis, arthritis or osteoporosis\] * Able to self-report history of daily gait freezing and/or festination for people with PD or gait and/or transfers affected by condition * Able to walk unsupported or using an aid for at least 5 minutes and satisfactory completion of the Canadian PARQ and if over 69 used to carrying out this level of exercise * Adult (+18 years old) * Normal or corrected-to-normal vision (Snellen Visual Acuity \> 12/18) or safe to mobilise with support * Montreal Cognitive assessment score \>21 or ability to follow 2 stage commands Healthy participants \[Phase 1,2,3\] * With no long-term conditions affecting movement * Able to walk unsupported or using an aid for at least 3 minutes and satisfactory completion of the Canadian PARQ and if over 69 used to carrying out this level of exercise * Adult (+18 years old) * Normal or corrected-to-normal vision (Snellen Visual Acuity \> 12/18) or safe to mobilise with support * Montreal Cognitive assessment score \>21 or ability to follow 2 stage commands Exclusion criteria Participants with Parkinson's * Any physical or mental condition affecting ability to safely participate in this level of activity and capacity to understand testing as demonstrated by ability to safely follow commands and pass the PARQ by the research team. * Cognitive impairment affecting ability to safely participate and follow instructions * Any injury or disorder that may affect balance (other than Parkinson's or referring primary condition) * Any skin conditions or broken skin in the calf and behind knee area * Deep brain stimulation or pacemaker implants or other implant that may interfere with the measurement system * Medications likely to affect eye sight or use of virtual reality sytstem Healthy participants * Any physical or mental condition affecting ability to safely participate in this level of activity and capacity to understand testing as demonstrated by ability to safely follow commands and pass the PARQ by the research team. * Cognitive impairment affecting ability to safely participate and follow instructions * Any injury or disorder that may affect balance (other than Parkinson's or referring primary condition) * Any skin conditions or broken skin in the calf and behind knee area * Deep brain stimulation or pacemaker implants or other implants that may interfere with the measurement system
Contact & Investigator
Helen Dawes, PhD
PRINCIPAL INVESTIGATOR
University of Exeter
Frequently Asked Questions
Who can join the NCT06733077 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Healthy Controls. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06733077 currently recruiting?
Yes, NCT06733077 is actively recruiting participants. Contact the research team at p.evangelidis@exeter.ac.uk for enrollment information.
Where is the NCT06733077 trial being conducted?
This trial is being conducted at Exeter, United Kingdom.
Who is sponsoring the NCT06733077 clinical trial?
NCT06733077 is sponsored by University of Exeter. The principal investigator is Helen Dawes, PhD at University of Exeter. The trial plans to enroll 80 participants.